Effects of plasmapheresis frequency on health status and exercise performance in men: a

randomized controlled trial

Running title: Plasmapheresis, health status and exercise performance

Alexandre Mortier¹, Jina Khoudary², Sophie van Doorslaer de Ten Ryen¹, Camille Lannoy, ¹

Nicolas Benoit¹, Nancy Antoine¹, Sylvie Copine¹, Hans Van Remoortel^{3,4}, Philippe

Vandekerckhove^{2,4}, Veerle Compernolle^{2,5}, Louise Deldicque^{1,6}

¹Institute of Neuroscience, UCLouvain, Louvain-la-Neuve, Belgium

²Blood Services, Belgian Red Cross, Mechelen, Belgium

³Centre for Evidence-Based Practice, Belgian Red Cross, Mechelen, Belgium

⁴Department of Public Health and Primary Care, Leuven Institute for Healthcare Policy, KU

Leuven, Leuven, Belgium

⁵Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

⁶Center of Investigation in Clinical Nutrition, UCLouvain, Louvain-la-Neuve, Belgium

Corresponding author:

Louise Deldicque, PhD

1, Place Pierre de Coubertin box L08.10.01

1348 Louvain-la-Neuve

louise.deldicque@uclouvain.be

Tel: +32 10 47 44 43

ABSTRACT

Objectives: To collect data on 1) haematological and biochemical markers, 2) physiological

and exercise-related parameters and 3) adverse events to get a comprehensive picture of the

safety of intensive or less intensive plasma donation protocols.

Methods: Sixty-three male subjects participated in this randomized controlled trial and were

divided into a low-frequency (LF, 1x/month, n=16), high-frequency (HF, 3x/month, n=16),

very high-frequency (VHF, 2x/week, n=16) and a placebo (P, 1x/month, n=15) group.

Biochemical, haematological, clinical, physiological and sport performance-related data were

collected before (D0), after 1½ month (D42) and after 3 months (D84).

Results: In VHF, red blood cells, haemoglobin and haematocrit levels decreased while

reticulocyte levels increased from D0 to D84. In both HF and VHF, plasma ferritin levels were

lower at D42 and D84 compared to D0. In VHF, the plasma levels of albumin, IgG, IgA and

IgM dropped from D0 to D42 and remained lower at D84 than at D0. In HF, plasma IgG, IgA

and IgM were lower at D42 and IgG and IgM were lower at D84 compared to D0. Few adverse

events (haematoma, anaemia, vasovagal reactions without syncope) were reported in HF and

VHF. Repeated plasma donation had no effect on blood pressure, body composition or exercise

performance.

Conclusion: Haematological and biochemical parameters were severely impacted when

plasmapheresis was repeated twice a week, mildly impacted with a frequency of three times per

month and not impacted with a frequency of once a month. Despite those changes, markers for

exercise performance were not altered when plasmapheresis, whatever the frequency, was

repeated over 3 months.

Keywords

Albumin, immunoglobulin, maximal oxygen consumption, maximal power output, donor

selection

Summary Box:

What is already known on this topic?

Plasmapheresis may induce a series of health consequences, such as adverse events of diverse severities. However, those events have mainly been studied separately and retrospectively with no appropriate placebo group.

What this study adds?

This is the first randomized controlled trial prospectively investigating the effects of repeated plasma donation on a whole range of health consequences, namely biochemical and haematological, blood pressure, body composition, adverse events and, exercise performance.

How this study might affect research, practice or policy?

Worldwide efforts need to be made to increase the amount of plasma collected for manufacturing plasma-derived product. To avoid negative effects to donors, a sustainable plasma supply should be based on a large donorbase of low-frequency donors.

INTRODUCTION

More and more inflammatory, neurological, haematological, and immunological diseases can be effectively treated with human plasma-derived products.¹ As such, the demand for plasma as the starting material for the manufacture of intravenous immunoglobulin and other plasma derivatives is growing significantly and is expected to continue to increase.² Future demand for intravenous immunoglobulin in developed countries is largely being driven by populations that are increasing in age and weight as well as the emergence of new indications. To increase the amount of collected plasma, one can expand the existing donorbase, collect higher volumes per donation or stimulate donors to donate more frequently. Increasing plasma collections, whether by increasing the volume per donation or the frequency, from returned donors can also reduce the risk of infectious disease transmission, as these donors have been shown to have a lower incidence of infectious disease markers.^{3 4}

Plasma donors in the United States may donate twice within 7 days as long as the interval between donations is at least 2 days.⁵ Prospective studies conducted in Germany, such as the safety of long-term intensive plasmapheresis (SIPLA) study, have demonstrated that up to 850ml of plasma, including anticoagulant, can be safely collected.⁶ However, only very few studies have prospectively looked at the effect of repeated intensive plasma donation and whether a control group was lacking^{6 7} or the control group was not randomized.⁸ The majority of the studies were retrospective⁹⁻¹⁴ or limited to one single donation¹⁵⁻¹⁷. We have recently found that repeated whole blood donation with a 3-month interval in between induced a drop in markers for iron status, which worsened with the number of donations.¹⁸ The repetition effect of the donations, whether whole blood or plasma, can be different from the effects measured after one single donation. It is therefore critical to test and document this repetitive effect to build trustable and valid guidelines concerning repetitive plasma donation. Up to now, each study has looked at a quite limited number of outcomes separately, namely biochemical and haematological, ⁶ ⁸ ¹⁰⁻¹³ ¹⁵ ¹⁶ blood pressure, ⁷ clinical symptoms and adverse events, ¹⁴ ¹⁵ bone

metabolism,⁹ and exercise performance.¹⁷ The aim of the present study was to collect data on 1) haematological and biochemical markers, 2) physiological and exercise-related parameters and 3) adverse events to get a comprehensive picture of the safety of intensive or less intensive plasma donation protocols over a 3-month period.

MATERIAL AND METHODS

Equity, diversity, and inclusion statement

The author group is gender balanced and consists of junior, mid-career and senior researchers from different disciplines; however, all members of the author group are from one country. Our study population included adult men from different socioeconomic backgrounds; thus, findings may not be generalizable to other populations. The influence of gender and age is considered in the discussion.

Subjects

Potential study participants were either new plasmapheresis donors or previous donors who had not donated for at least 2 weeks. Eligible study participants were randomly assigned, via a computer-generated randomization table, into a placebo group (P), a low-frequency group (LF, 1 plasma donation per month), a high-frequency frequency group (HF, 3 plasma donations per month) and a very high-frequency group (VHF, 2 plasma donations per week), to participate in this longitudinal study. The donation frequency regimen in the VHF group (2x/week) represents the current plasma donation regulation in countries such as Austria, Germany, Hungary, USA, and Canada whereas most other countries have a minimal donation interval of 14 days. The placebo group underwent a placebo donation at the same frequency as LF (1x/month). All participants were blinded to the group selection.

Inclusion criteria were as follows: male, age 18 to 50 y, body mass index (BMI) 20 to 28 kg·m²
1, and no contraindication to perform maximal intensity exercise assessed by the physical

activity readiness questionnaire (PAR-Q). During the whole duration of the study, subjects were asked to maintain their habitual lifestyle, i.e., physical activity and diet. All participants provided written informed consent after the explication of all potential risks of the study and the right to withdraw at any time. This study was conducted at the UCLouvain in Belgium from March 2022 to December 2022. The study was approved by the Ethics Committee of UCLouvain and the investigation was performed according to the principles outlined in the Declaration of Helsinki. The study (RK2020) was registered at clinicaltrials.gov and received the identifier NCT05815615.

Experimental procedures

One week before the first plasma donation (D0, visit 1), subjects reported to the exercise physiology laboratory. First, systolic and diastolic blood pressure was measured automatically (Omron) in the supine position. Then, five blood samples were taken in an antecubital vein from the non-dominant arm: three 4-ml EDTA tubes, one 8-ml clot activator tube and one 4-ml sodium fluoride/potassium oxalate tube. After blood sampling, a maximal strength test of the dominant arm was performed using an electronic dynamometer (Grip-D, Takei, Japan) followed by a maximal strength test (1RM) with the dominant leg on a leg extension machine (ProDual, Body-Solid, IL, USA). After an individualised and standardised warm-up protocol, the 1RM test consisted of a maximum of 5 attempts interspersed by 3-min rest. The 1RM corresponded to the highest load lifted once with a correct technique. Then, body mass and height were measured (Seca GmbH., Hamburg, Germany) and body composition (bone mineral content, fat-free mass and fat mass) was assessed by dual energy X-ray absorptiometry (DXA) scan (Discovery W, Hologic Inc., MA, USA). Finally, a progressive test on a bicycle ergometer (Cyclus 2, RBM elektronik automation GmbH, Leipzig, Germany) was performed to measure peak oxygen consumption (VO₂ peak). The test started at 70 watts (W), followed by incremental loads of 30 W every 2 min until exhaustion. The maximal power output (Pmax) was calculated as the last step completed plus the last increment corrected for the sustained duration, which corresponded to the total time of the test. VO₂, carbonic dioxide production (VCO₂) (Medisoft Ergocard, MGC Diagnostics Corporation, MN, USA) as well as heart rate (HR) (Polar, Kempele, Finland) were continuously monitored during the test. Oxygen pulse was calculated by dividing VO₂ peak and HRmax at the end of the test. Blood lactate was measured before, during (at 190 W), and at the end of the test by taking a capillary blood sample (5 μl) from an earlobe (Lactate Pro, Arkray, Japan). The whole sampling and testing procedure was repeated 42 days (D42, visit 2) and 84 days (D84, visit 3) after the first plasma donation in exactly the same conditions. Adverse events, categorized according to international standards²⁰, were recorded in the blood information system throughout the whole experimental trial. Citrate reactions were not considered in our analysis, since preventive calcium supplements were provided standardly to the regular donors.

Plasma donation

One week after blood sampling and exercise pretesting (D0 or visit 1), participants reported to the Red Cross Center in Leuven or Mechelen (Belgium). They underwent a plasma donation of 650 ml (exclusive anticoagulant) according to the Belgian Law of 01/02/2005, without exceeding 20% of total body volume during or 16% of total body volume at the end of the plasma donation (donation group), or had a similar sensation of undergoing a plasma donation (placebo group), by infusing NaCl 0.9% using a NexSys PCS device (Haemonetics). During each donation or simulation of donation, the puncture arm was shielded, and subjects were listening to music through a headset.

Blood analyses

Each tube was centrifuged for 10 min at 2000 g at 4°C and analyzed within 24 h following blood drawing. The supernatant was collected and stored at -80 °C. The following parameters

were analyzed in a medical analysis laboratory (Lims mbnext group Europe, LLN, Belgium): red blood cell, haemoglobin, haematocrit, reticulocyte, iron, ferritin, C-reactive protein (CRP), glycemia, insulinemia, glycated haemoglobin (HbA1c), creatine kinase (CK), total cholesterol, albumin, immunoglobulin (Ig) A, IgG and IgM.

Statistical analysis

A statistical power analysis was performed to determine the optimal number of subjects needed to find a difference in total serum protein mean of 10%¹⁰ with a standard deviation corresponding to 8% and a power of 80% according to the calculator developed by Wang and Ji. ²¹ Drop-outs were not taken into consideration in statistical analysis. Potential differences in subjects' characteristics at baseline were analyzed with a one-way ANOVA (IBM SPSS Statistics, Version 28.0., Armonk, NY, USA). A mixed ANOVA model for repeated measures (SAS Statistical Software 9.4, SAS Institute, Cary, NC, USA) was used with the subjects as a random variable and groups (placebo and donations) and condition (time) as fixed independent variables. The p-values of the main effects can be found in Table S1. The model used Kenward-Roger approximation of degree of freedom with compound symmetry variance-covariance structure. When appropriate, contrast analyses were performed to compare means, applying a Sidak correction. Linear mixed models for repeated measures give unbiased results in the presence of missing data and take potential differences at baseline into account. Normality of residuals was tested using a QQ plot. The total amount of adverse events and the adverse event rate (per 50 donations) were calculated. Statistical significance was set at p<0.05. All values are expressed as mean \pm SEM, except donation history as a median [IQR, interquartile range].

RESULTS

Subject characteristics

Seventy-two volunteers were enrolled in the study: 17 in the Placebo, 16 in the LF, 20 in the HF and 19 in the VHF group (Fig. 1). Nine subjects (2 in the placebo group, 4 in the HF group and 3 in the VHF group) gave up before the end of the study. Withdrawal from the study was due to personal reasons or impossibility to comply with the repeated appointments. As they were incomplete, the data of the drop-outs were not included in the analyses, resulting in a total number of 63 subjects: 15 in the Placebo, 16 in the LF, 16 in the HF and 16 in the VHF group. All participants were regular donors, except one new donor (who was allocated to the LF group). At the start of the study, the 4 groups were not different regarding age, BMI, the amount of physical activity per week, VO₂peak and donation history (Table S2).

Forty-nine study participants were 100% compliant to the corresponding donor regimen (5 (31%) in the VHF group, 14 (88%) in the HF group, 15 (94%) in the LF group, and 15 (100%) in the placebo group). In het VHF group, 6 participants missed 1 donation, 2 participants missed 2-3 donations, 2 participants missed 5-6 donations, and 1 participant missed 10 donations.

High-frequency and very high-frequency donation affect haematology

Red blood cells, haemoglobin, haematocrit, reticulocyte, iron and ferritin levels all evolved differently between the 4 groups after repeated plasma donation (main group or main group*time effect, p<0.05-0.001, Table S1 and Figure 2A and B). In VHF, red blood cells (p<0.001), haemoglobin (p<0.001) and haematocrit (p=0.003) levels decreased while reticulocytes levels (p<0.001) increased from D0 to D84 (Table 1 and Figure 2A and B). In addition, reticulocytes levels were higher at D42 compared to D0 (p<0.001). In both HF and VHF, plasma ferritin levels were lower at D42 (p=0.039 in HF; p=0.001 in VHF) and at D84 (p=0.008 in HF; p<0.001 in VHF) compared to D0. Except for red blood cells, all aforementioned effects of repeated plasma donation in HF and VHF were different from P at the same time point.

Very high-frequency donation lowers HbA1c

A main time and/or a group*time effect was present for glycemia, insulinemia and HbA1c (p<0.05-0.001, Table S1). Glycemia decreased from D0 to D84 in HF (p=0.002) and in VHF (p=0.042) and was lower in both HF and VHF at D84 compared to P and LF (p<0.05) (Table 1). Insulinemia increased from D0 to D42 in HF (p=0.035) and VHF (p=0.019). In VHF, plasma HbA1c levels decreased from D0 to D42 (p=0.007) and from D42 to D84 (p=0.015). A main time effect was found for plasma total cholesterol levels (p<0.001). Compared to D0, total cholesterol levels were higher at D42 in HF (p<0.001) and at D84 in P (p=0.014), LF (p=0.049) and HF (p=0.005).

Very high-frequency scheme severely affects plasma albumin and immunoglobulin levels Plasma albumin, IgG, IgA and IgM levels all evolved differently between the 4 groups after repeated plasma donation (main group*time effect, p<0.001, Table S1 and Figure 2C-F). In VHF, the plasma levels of albumin, IgG, IgA and IgM dropped substantially from D0 to D42 (p<0.001) and remained lower at D84 than at D0 (p<0.001) (Table 1). Albumin and IgG levels at D42 and D84 in VHF were lower than P, LF and HF at the same time (p<0.01-0.001). In HF, compared to D0, plasma IgG (p<0.001), IgA (p=0.011) and IgM (p=0.006) were lower at D42 and IgG (p<0.001) and IgM (p<0.001) lower at D84. CRP, CK, SBP and DBP were unaffected by repeated plasma donation.

No effect of repeated plasma donation on body composition

A main time, but no group nor group*time, effect was found for fat free mass (p=0.012), fat free mass + bone mineral content (p=0.012), fat mass (p<0.001) and % fat (p<0.001) (Table S1). Fat free mass and fat free mass + bone mineral content was lower at D84 compared to D0 (p=0.040 and p=0.049, respectively) and D42 (p=0.008 and p=0.009, respectively) in P (Table 2). Fat mass increased from D0 to D84 in HF (p=0.038) and VHF (p=0.041). In addition, fat

mass increased from D42 to D84 in P (p=0.016) and VHF (p=0.002), which resulted in an increase in fat percentage between D42 and D84 in P (p=0.006) and VHF (p=0.003). No main effect was found for body mass, BMI and bone mineral content.

No effect of repeated plasma donation on exercise performance

A main time, but no group nor group*time, effect was found for maximal power output (p=0.006, Fig. 3A), VO₂peak (p=0.001, Fig. 3B) and oxygen pulse (p=0.002) (Table S1). Maximal power output decreased from D0 to D42 in LF (p=0.019) and from D0 to D42 (p=0.013) and D84 (p=0.012) in VHF (Fig. 3A and Table 3). VO₂peak was higher at D42 compared to D0 (p=0.009) and compared to D84 (p=0.038) in HF (Fig. 3B). Finally, oxygen pulse was higher at D42 in P (p=0.037) and HF (p=0.006) and higher at D84 (p=0.027) in LF compared to D0. No main effect was found for lactate at 190W, lactate post-exercise, maximal ventilation and maximal heart rate, maximal quadriceps (Fig. 3C) and arm strength.

Few adverse events were reported in the HF and VHF group

The occurrence of adverse events was monitored in each group during the whole experimental trial (Table S3). Five haematomas were present in HF (3 events in 3 donors, adverse event rate: 1.08) and VHF (2 events in 1 donor, adverse event rate: 0.28). A total amount of 5 vasovagal reactions were reported, 1 in HF (1 donor, adverse event rate: 0.36) and 4 in VHF (3 donors, adverse event rate: 0.57). Six anaemia events (in 5 donors, adverse event rate: 0.85) were detected in VHF. No other (major) events were reported.

DISCUSSION

For the first time, data on 1) haematological and biochemical markers, 2) physiological and exercise-related parameters and 3) adverse events were prospectively collected over 3 months to get a comprehensive picture of the health consequences of intensive or less intensive plasma

This is the first randomized controlled trial prospectively investigating the health consequences of repeated plasma donation. Most research studies in this domain have an observational study design, with different study limitation (e.g. not controlled for confounding), resulting in high uncertainty on the (causal) link between repeated plasma donation and health consequences.²²-²⁵ One previous non-randomized controlled study compared total serum protein, albumin, IgG, IgA and IgM levels after weekly or bi-weekly (>14 days) plasmapheresis for 6 months to levels obtained in regular blood donors. 8 This study showed that total protein and IgG levels in the weekly group were lower than those in the control and the bi-weekly group, but remained well within the normal ranges. Albumin, IgA and IgM levels were not modified by plasmapheresis. Our high-frequency group, corresponding more or less to the weekly group in Ciszewski et al, had lower plasma ferritin, IgG, IgA and IgM levels after 3 months plasma donation. Our very high-frequency group was even more impacted, with haemoglobin and albumin levels being downregulated as well compared to the start of plasma donation and compared to the placebo group. Except for IgG in the very high-frequency group, the drop in all other haematological and biochemical parameters in the high-frequency and/or very high-frequency group did not cross the lower acceptable limits in average. Of note, before the start of the study, IgG levels were slightly lower in the low- and very-high frequency group compared to the placebo group but still well within physiological range. Lower ferritin values were previously reported in frequent plasma donors compared to non-donors, 11 13 with ferritin levels being negatively

Alongside determining the effects of repeated plasma donation on haematological and biochemical markers, the second aim of the study was to investigate the functional and physiological impact of repeated donation. We found no effect of 3-month plasma donation on blood pressure, body mass, body composition, markers for endurance performance and maximal strength. Systolic and diastolic blood pressure were found to be decreased after 4-month plasma donation at intervals of less than 14 days in donors with high baseline blood pressure levels. ⁷ Here, in donors with normal blood pressure levels at the start of the study, no modification of blood pressure was observed, even in the most intensive groups. Based on the decrease in some haematological parameters and a previous study looking at the effect of one

single plasma donation on exercise performance¹⁷, we could have expected a decrease in markers for endurance performance in the very high-frequency group. Neither maximal power output, maximal oxygen consumption, nor blood lactate levels were modified by repeated plasma donation, whatever the intensity of the donation. One previous study looked at the effects of one single plasma donation on time to exhaustion, maximal oxygen consumption and markers for anaerobic capacity, i.e. blood lactate levels and maximal accumulated oxygen deficit. ¹⁷ While maximal oxygen consumption was unaffected by plasma donation, time to exhaustion, blood lactate levels and maximal accumulated oxygen deficit were all decreased by 10 to 20%. Our results suggest that the negative effects of acute plasma donation on endurance performance are not observed on the longer term, when donation is repeated and performance is determined a few days after the last donation in basal conditions. It is important to highlight that, despite the downregulation of key haematological parameters, endurance performance was not affected. We previously found that a partial dissociation and/or delay may be found between the regulation of haematological parameters, and more particularly those related to the iron status, and endurance performance after repeated blood donation. ^{18 26} Given the importance of iron status for exercise performance²⁷, it might not be excluded that the 3-month period of investigation was too short to induce detectable downregulation of endurance and strength performance in the very high-frequency group.

Finally, no serious adverse events were reported and only few events (anemia, hematomas, vasovagal reactions without syncope) were present in the high-frequency and very high-frequency groups, which are classically reported by others after plasma donation. ⁶ ¹⁴ ¹⁵

Clinical implications

Very high-frequency donation affects IgG levels of donors down to a level that may impact their immune system and affects haematological parameters. Therefore, countries should rely on large donor bases with donors donating at low-frequency to ensure a sustainable plasma supply while avoiding negative health effect to their donors.

Limitations

Firstly, only middle-aged men have been included in this study. Therefore, the external validity is limited and the present results cannot be extrapolated to female or elderly donor populations. Further studies should investigate whether those results are similar in women and older people. Secondly, this randomized controlled trial lasted for 3 months. It may not be excluded that the severe haematological and biochemical changes measured during this period in the very-high frequency group, although not falling below normal values for most of them, will not affect physiological function and exercise performance on a longer term. Thirdly, the randomization procedure was suboptimal since allocation to the high-frequency/very high-frequency group was sometimes in conflict with the availability of the participant. Therefore, the donor was

assigned to the first available position on the randomization list that did not conflict with his

availability. The impact of this suboptimal randomization procedure was considered to be

Conclusion

limited.

Haematological and biochemical parameters were severely impacted when plasmapheresis was repeated twice a week, mildly impacted with a frequency of three times per month and not impacted with a frequency of once a month. Despite those changes, markers for exercise performance were not altered when plasmapheresis, whatever the frequency, was repeated over 3 months.

ACKNOWLEDGMENT

We thank Anna Piperi, Marine Buchet and Elena De Bock for technical assistance and Céline Bugli for the statistical analyses. The study was funded by the Science Foundation of the Belgian Red Cross.

Authorship contributions

Protocol design: VC, PV, LD; data acquisition: AM, JK, SvDdtR, CL, NB, NA, SC, VC, LD; data interpretation: HVR, PV, VC, LD; manuscript drafting: AM, LD; manuscript revision and approval: AM, JK, SvDdtR, CL, NB, NA, SC, HVR, PV, VC, LD.

Disclosure of conflict of interest

No conflict of interest to be disclosed.

REFERENCES

- Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. *Clin Exp Immunol* 2005;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x [published Online First: 2005/09/24]
- 2. Robert P. Global plasma demand in 2015. Pharma Policy Law 2009;11:359-67.
- 3. Soldan K, Barbara JA, Ramsay ME, et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. *Vox Sang* 2003;84(4):274-86. doi: 10.1046/j.1423-0410.2003.00296.x [published Online First: 2003/05/22]
- 4. Zou S, Musavi F, Notari EP, et al. Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008. *Transfusion* 2010;50(7):1487-94. doi: 10.1111/j.1537-2995.2010.02621.x [published Online First: 2010/03/30]
- Administration UFaD. Compliance policy guides manual: plasmapheresis—48 hour period between plasmapheresis procedures. CPG 7123.23. In: Administration UFaD, ed. Rochester (MD), 2000.
- 6. Schulzki T, Seidel K, Storch H, et al. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA). *Vox Sang* 2006;91(2):162-73. doi: 10.1111/j.1423-0410.2006.00794.x
- 7. Rosa-Bray M, Wisdom C, Marier JF, et al. The effect of plasmapheresis on blood pressure in voluntary plasma donors. *Vox Sang* 2015;108(1):11-7. doi: 10.1111/vox.12188

 [published Online First: 20140828]
- 8. Ciszewski TS, Ralston S, Acteson D, et al. Protein levels and plasmapheresis intensity.

 Transfus Med 1993;3(1):59-65. doi: 10.1111/j.1365-3148.1993.tb00105.x

- 9. Amrein K, Katschnig C, Sipurzynski S, et al. Apheresis affects bone and mineral metabolism. *Bone* 2010;46(3):789-95. doi: 10.1016/j.bone.2009.11.008 [published Online First: 2009/11/20]
- 10. Laub R, Baurin S, Timmerman D, et al. Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations. *Vox Sang* 2010;99(3):220-31. doi: 10.1111/j.1423-0410.2010.01345.x [published Online First: 2010/09/16]
- 11. Li H, Condon F, Kessler D, et al. Evidence of relative iron deficiency in platelet- and plasma-pheresis donors correlates with donation frequency. *J Clin Apher* 2016;31(6):551-58. doi: 10.1002/jca.21448 [published Online First: 2016/02/27]
- 12. Schreiber GB, Brinser R, Rosa-Bray M, et al. Frequent source plasma donors are not at risk of iron depletion: the Ferritin Levels in Plasma Donor (FLIPD) study. *Transfusion* 2018;58(4):951-59. doi: 10.1111/trf.14489 [published Online First: 20180309]
- 13. Tran-Mi B, Storch H, Seidel K, et al. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. *Vox Sang* 2004;86(3):189-97. doi: 10.1111/j.0042-9007.2004.00408.x
- 14. Yuan S, Gornbein J, Smeltzer B, et al. Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections. *Transfusion*2008;48(6):1213-9. doi: 10.1111/j.1537-2995.2008.01674.x [published Online First: 2008/03/19]
- 15. Buzza M, Marks DC, Capper H, et al. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis. *Transfusion* 2012;52(8):1806-13. doi: 10.1111/j.1537-2995.2012.03561.x [published Online First: 2012/02/22]

- 16. Ghio M, Contini P, Ansaldi F, et al. Immunomodulation due to plasma or plasma-platelet apheresis donation: Events occurring during donation procedures. *J Clin Apher* 2015;30(4):204-11. doi: 10.1002/jca.21362 [published Online First: 2014/10/01]
- 17. Hill DW, Vingren JL, Burdette SD. Effect of plasma donation and blood donation on aerobic and anaerobic responses in exhaustive, severe-intensity exercise. *Appl Physiol Nutr Metab* 2013;38(5):551-7. doi: 10.1139/apnm-2012-0361 [published Online First: 2013/05/15]
- 18. Meurrens J, Steiner T, Ponette J, et al. Effect of Repeated Whole Blood Donations on Aerobic Capacity and Hemoglobin Mass in Moderately Trained Male Subjects: A Randomized Controlled Trial. Sports Med Open 2016;2(1):43. doi: 10.1186/s40798-016-0067-7 [published Online First: 2016/11/23]
- 19. Purohit M, Berger M, Malhotra R, et al. Review and assessment of the donor safety among plasma donors. *Transfusion* 2023 doi: 10.1111/trf.17369 [published Online First: 20230419]
- 20. International society of blood transfusion working party on haemovigilance network and the AABB donor haemovigilance working group. Standard for surveillance of complications related to blood donation 2014 [Available from:

 https://www.aabb.org/docs/default-source/default-document-library/resources/donor-standard-definitions.pdf?sfvrsn=21834fa4_0 accessed 9 February 2023.
- 21. Wang X, Ji X. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies. *Chest* 2020;158(1S):S12-S20. doi: 10.1016/j.chest.2020.03.010 [published Online First: 2020/07/14]
- 22. Grgicevic D. Influence of long-term plasmapheresis on blood coagulation. *Ric Clin Lab* 1983;13(1):21-31.
- 23. Grgicevic D, Pistotnik M, Pende B. Observation of the changes of plasma proteins after long term plasmapheresis. *Dev Biol Stand* 1980;48:279-86.


- 24. Rosa-Bray M, Wisdom C, Wada S, et al. Prospective multicentre study of the effect of voluntary plasmapheresis on plasma cholesterol levels in donors. *Vox Sang* 2013;105(2):108-15. doi: 10.1111/vox.12031 [published Online First: 20130320]
- 25. Salvaggio J, Arquembourg P, Bickers J, et al. The effect of prolonged plasmapheresis on immunoglobulins, other serum proteins, delayed hypersensitivity and phytohemagglutinin-induced lymphocyte transformation. *Int Arch Allergy Appl Immunol* 1971;41(6):883-94. doi: 10.1159/000230580
- 26. Pachikian B, Naslain D, Benoit N, et al. Iron supplementation limits the deleterious effects of repeated blood donation on endurance sport performance but not on iron status. *Blood Transfus* 2020;18(5):334-47. doi: 10.2450/2020.0087-20 [published Online First: 2020/09/16]
- 27. Sim M, Garvican-Lewis LA, Cox GR, et al. Iron considerations for the athlete: a narrative review. *Eur J Appl Physiol* 2019;119(7):1463-78. doi: 10.1007/s00421-019-04157-y [published Online First: 20190504]


FIGURES LEGENDS

Fig. 1. Subjects flow chart.

Fig. 2. Plasma haemoglobin, ferritin, albumin and immunoglobulin levels. Evolution of plasma haemoglobin (A), ferritin (B), albumin (C), Immunoglobulin G (IgG, D), IgA (E) and IgM (F) levels before (D0), during (D42) and after (D84) the 3-month trial in the placebo and donation groups. Data are expressed as means ± SEM. n=15 in Placebo, n=16 in each of the 3 donation groups. *p<0.05, ***p<0.001 different from D0, same group. *p<0.05, ***p<0.001 D84 vs D42, same group. \$p<0.05, \$\$p<0.01, \$\$\$p<0.01, \$\$\$p<0.01 different from P, same time. \$\$p<0.05, \$\$\$p<0.01, \$\$\$\$p<0.001 different from HF, same time.

Fig. 3. Markers for endurance and strength performance. Evolution of the maximal power output (A), peak oxygen consumption (VO₂peak, B) and maximal strength of the quadriceps (1RM, C) before (D0), during (D42) and after (D84) the 3-month trial in the placebo and donation groups. Data are expressed as means ± SEM. n=15 in Placebo, n=16 in each of the 3 donation groups. *p<0.05, *#p<0.01 different from D0, same group. *p<0.05 D84 vs D42, same group.








Table 1. Effects of repeated plasma donation on hematological parameters and blood pressure

		D0	D42	D84
RBC	P	4.84±0.07	4.91±0.09	5.03±0.07###,*
$(10^6 \cdot \text{mm}^{-3})$	LF	5.01±0.14	4.99 ± 0.14	5.01±0.14
	HF	4.94 ± 0.08	4.96 ± 0.08	5.03 ± 0.08
	VHF	4.99 ± 0.08	4.90 ± 0.09	4.77±0.06###,*
Haemoglobin	P	14.5±0.3	14.7±0.3	15.1±0.2###,*
(g·dl-1)	LF	14.6±0.1	14.5±0.1	14.5±0.2
	HF	14.7±0.3	14.8±0.2	15.0±0.2
	VHF	14.6±0.2	14.4±0.3	13.9±0.2****,§§§,\$,£££
Haematocrit	P	41.8 ± 0.7	42.3±0.7	43.5±0.7###,*
(%)	LF	42.0±0.3	42.1±0.3	42.0 ± 0.5
	HF	42.3±0.6	42.3±0.7	43.2±0.5
	VHF	42.1±0.4	41.8±0.7	$40.6 \pm 0.4^{\text{##,*,§§§,fff}}$
Reticulocyte	P	1.3±0.1 [£]	1.4 ± 0.1	1.3±0.1
(%)	LF	1.3±0.1 [£]	1.3 ± 0.1	1.3±0.1
	HF	1.5±0.1	1.5 ± 0.1	1.5±0.1§
	VHF	1.3±0.1 [£]	1.6±0.1###,§,\$	1.6±0.1****,§,\$
Iron	P	109.3±12.0	109.8 ± 12.3	122.7 ± 13.9
$(\mu g \cdot dl^{-1})$	LF	106.8 ± 10.2	100.3±7.4	103.3±7.1
	HF	83.6 ± 10.1	106.4 ± 10.6	91.3±9.6§
	VHF	75.7±10.0§,\$	78.8±9.1§	65.0±8.2§§§,\$\$
Ferritin	P	74.4 ± 14.8	71.5 ± 11.7	82.7±14.4
$(\mu g \cdot l^{-1})$	LF	78.7 ± 19.4	69.9 ± 17.8	74.6 ± 16.5
	HF	46.8 ± 6.5	31.2±3.6 ^{#,§,\$}	$31.0 \pm 3.7^{\#\#,\S\S,\$\$}$
	VHF	50.2 ± 8.7	$30.7 \pm 3.5^{\#\#,\$,\$}$	$20.1 \pm 2.5^{\text{###}, \$\$\$,\$\$}$
CRP	P	2.6 ± 0.6	2.0 ± 0.4	2.2±0.4
$(mg \cdot l^{-1})$	LF	3.8 ± 1.4	2.3 ± 0.5	2.8 ± 0.5
	HF	3.3 ± 0.7	2.7 ± 0.8	3.4 ± 0.7
	VHF	3.0 ± 0.9	2.6 ± 0.4	2.1±0.5
Glycemia	P	92.5±3.5	82.3±5.3	91.4±4.6
$(mg \cdot dl^{-1})$	LF	91.6±4.2	91.9±3.4	92.4±5.6
	HF	94.9±3.1	94.2±4.2§	$78.6 \pm 3.7^{\#\#,**,\S,\$}$
	VHF	90.6 ± 2.4	$82.4 \pm 3.5^{\text{f}}$	79.9±3.6 ^{#,§,\$}
Insulinemia	P	73.5±12.2	89.6 ± 16.4	92.6±14.7
$(pmol \cdot l^{-1})$	LF	76.3 ± 17.2	83.1 ± 12.7	98.6 ± 15.0
	HF	76.8 ± 15.9	138.2±31.4#	87.0±18.3*
	VHF	77.5 ± 15.7	133.4±47.0#	114.9±29.9
HbA1c	P	5.2 ± 0.1	5.2 ± 0.1	5.2±0.1
(%)	LF	5.3±0.1	5.3 ± 0.1	5.3±0.1
	HF	5.3±0.1	5.3 ± 0.1	5.3±0.1
	VHF	5.3±0.1	5.2±0.1#	5.1±0.1###,*,\$
CK	P	124.9 ± 16.2	152.3±21.1	142.6±15.3
(U/l)	LF	295.0 ± 101.8	149.1 ± 18.5	170.2 ± 17.7
	HF	147.6 ± 14.1	151.2 ± 17.0	145.5±11.9
	VHF	188.2 ± 39.1	152.2±19.3	179.9±31.8
Total cholesterol	P	162.7 ± 10.3	167.1 ± 8.9	$175.9 \pm 8.2^{\#}$
$(mg \cdot dl^{-1})$	LF	161.3±7.2	167.9±7.3	171.4±8.9#
	HF	160.5±5.6	180.6±8.2###	175.2±8.1##

VHF 182.9±10.9 188.4±12.5 189.4±10.8 Albumin P 43.7±0.9 44.4±0.6 45.9±0.7###.* (g·1·1) LF 44.0±0.6 43.7±0.7 43.7±0.7 HF 44.4±0.6 43.5±0.6 44.7±0.8 VHF 45.5±0.8 40.5±0.6###.\$\$\$,\$S.S.EE 40.6±0.6###.\$\$\$,\$S.S.EE IgA P 2.24±0.24 2.35±0.26 2.34±0.27 (g·1·1) LF 1.91±0.22 1.95±0.22 1.89±0.22 HF 2.17±0.17 1.93±0.14# 2.10±0.16 VHF 2.49±0.28 2.04±0.22### 2.06±0.22### IgG P 10.58±0.45 11.02±0.50 10.59±0.48 (g·1·1) LF 9.25±0.55\$ 8.53±0.54\$\$\$ 8.70±0.55\$\$\$ HF 10.04±0.45 8.69±0.48###.\$\$\$ 8.70±0.55\$\$\$ VHF 9.23±0.43\$ 6.12±0.30###.\$\$\$,\$SS.S.EEE 5.73±0.35###.\$\$\$,\$SS.EEE IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·1·1) LF 0.90±0.09 0.82±0.08 0.82±0.08# HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#.\$ 131±3 VHF 130±3 136±3#.\$ 135±3 VHF 130±3 136±3#.\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2 VHF 82±2 77±5 81±2 VHF 82±2 77±5 81±2 VHF 82±2 77±5 81±2 VHF 82±2 77±5 81±2 VHF 10.0±0.0±0.0±0.0±0.0±0.0±0.0±0.0±0.0±0.0					
(g·l·¹) LF 44.0±0.6 43.7±0.7 43.7±0.7\$ HF 44.4±0.6 43.5±0.6 44.7±0.8 VHF 45.5±0.8 40.5±0.6##,\$\$\$.\$\$.\$£.££ 40.6±0.6##,\$\$\$.\$\$.\$\$.\$£.£££ IgA P 2.24±0.24 2.35±0.26 2.34±0.27 (g·l·¹) LF 1.91±0.22 1.95±0.22 1.89±0.22 HF 2.17±0.17 1.93±0.14# 2.10±0.16 VHF 2.49±0.28 2.04±0.22### 2.06±0.22### IgG P 10.58±0.45 11.02±0.50 10.59±0.48 (g·l·¹) LF 9.25±0.55\$ 8.53±0.54\$\$\$ 8.70±0.55\$\$ VHF 10.04±0.45 8.69±0.48###,\$\$\$ 8.43±0.38###,\$\$ VHF 9.23±0.43\$ 6.12±0.30###,\$\$\$ 8.43±0.38###,\$\$\$ VHF 0.90±0.09 0.82±0.08 0.82±0.08# VHF 0.91±0.10 0.62±0.06### VHF 0.91±0.10 0.62±0.06### SBP P 129±3 135±4#,\$\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 130±3 136±3#,\$\$ 135±3 VHF 130±3 136±3#,\$\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		VHF	182.9±10.9	188.4±12.5	189.4±10.8
HF	Albumin	P	43.7 ± 0.9	44.4 ± 0.6	45.9±0.7###,*
IgA P 2.24±0.24 2.35±0.26 2.34±0.27 (g·1·1) LF 1.91±0.22 1.95±0.22 1.89±0.22 HF 2.17±0.17 1.93±0.14# 2.10±0.16 VHF 2.49±0.28 2.04±0.22### 2.06±0.22### IgG P 10.58±0.45 11.02±0.50 10.59±0.48 (g·1·1) LF 9.25±0.55 [§] 8.53±0.54 ^{§§§} 8.70±0.55 ^{§§} HF 10.04±0.45 8.69±0.48##,§§§ 8.43±0.38##,§§ VHF 9.23±0.43 [§] 6.12±0.30##,§§§,SSS,EEE 5.73±0.35###,§§§,SSS,EEE IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·1·1) LF 0.90±0.09 0.82±0.08 0.82±0.08* IgM P 0.86±0.08 0.79±0.07## 0.73±0.08### (g·1·1) LF 0.90±0.09 0.82±0.08 0.82±0.08* UF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4* 131±3 UF 130±3 136±3* 135±3	$(g \cdot l^{-1})$	LF	44.0 ± 0.6	43.7 ± 0.7	43.7±0.7§
IgA P 2.24±0.24 2.35±0.26 2.34±0.27 (g·1¹) LF 1.91±0.22 1.95±0.22 1.89±0.22 HF 2.17±0.17 1.93±0.14 [#] 2.10±0.16 VHF 2.49±0.28 2.04±0.22 ^{###} 2.06±0.22 ^{###} IgG P 10.58±0.45 11.02±0.50 10.59±0.48 (g·1¹) LF 9.25±0.55 [§] 8.53±0.54 ^{§§§} 8.70±0.55 ^{§§} 8.70±0.55 ^{§§} HF 10.04±0.45 8.69±0.48 ^{###,§§§} 8.43±0.38 ^{###,§§} 8.43±0.38 ^{###,§§} VHF 9.23±0.43 [§] 6.12±0.30 ^{###,§§§,SSS,EEE} 5.73±0.35 ^{###,§§§,SSS,EEE} 5.73±0.35 ^{###,§§§,SSS,EEE} IgM P 0.83±0.10 0.86±0.10 0.89±0.11 0.89±0.11 0.21° 0.80±0.08 [#] 0.82±0.08 0.82±0.08 [#] 0.82±0.08 ^{###} 0.79±0.07 ^{###} 0.73±0.08 ^{###} 0.66±0.06 ^{###} SBP P 129±3 135±4 ^{#,§} 131±3 131±3 131±3 135±3 135±3 135±3 135±3 135±3 135±3 135±3 135±3 135±3 135±2 145		HF	44.4 ± 0.6	43.5±0.6	44.7 ± 0.8
Cg·l ⁻¹		VHF	45.5 ± 0.8	$40.5{\pm}0.6^{\text{###,§§§,$\$,££}}$	$40.6{\pm}0.6^{\text{###,§§§,$\$,£ff}}$
HF 2.17±0.17 1.93±0.14# 2.10±0.16 VHF 2.49±0.28 2.04±0.22### 2.06±0.22### IgG P 10.58±0.45 11.02±0.50 10.59±0.48 (g·1·1) LF 9.25±0.55\$ 8.53±0.54\$\$\$ 8.70±0.55\$\$ HF 10.04±0.45 8.69±0.48###.\$\$\$ 8.43±0.38###.\$\$\$ VHF 9.23±0.43\$ 6.12±0.30###.\$\$\$.\$\$\$.£££ 5.73±0.35###.\$\$\$.\$\$\$.£££\$ IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·1·1) LF 0.90±0.09 0.82±0.08 0.82±0.08# HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#.\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3#.\$ 135±3 VHF 130±3 136±3#.\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	IgA	P	2.24 ± 0.24	2.35 ± 0.26	2.34 ± 0.27
VHF 2.49±0.28 2.04±0.22### 2.06±0.22### IgG	$(g \cdot l^{-1})$	LF	1.91 ± 0.22	1.95 ± 0.22	1.89 ± 0.22
IgG P 10.58±0.45 11.02±0.50 10.59±0.48 (g·l·l) LF 9.25±0.55 [§] 8.53±0.54 ^{§§§} 8.70±0.55 ^{§§} HF 10.04±0.45 8.69±0.48 ^{###,§§§} 8.43±0.38 ^{###,§§} VHF 9.23±0.43 [§] 6.12±0.30 ^{###,§§§,SSS,£EE} 5.73±0.35 ^{###,§§§,SSS,£EE} IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·l·l) LF 0.90±0.09 0.82±0.08 0.82±0.08 ^{##} HF 0.86±0.08 0.79±0.07 ^{##} 0.73±0.08 ^{###} VHF 0.91±0.10 0.62±0.06 ^{###} 0.66±0.06 ^{###} SBP P 129±3 135±4 ^{#,§} 131±3 (mmHg) LF 129±2 126±2 132±3 VHF 130±3 136±3 ^{#,§} 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		HF	2.17 ± 0.17	$1.93{\pm}0.14^{\#}$	2.10 ± 0.16
(g·l-1) LF 9.25±0.55\$ 8.53±0.54\$\$\$ 8.70±0.55\$\$\$ HF 10.04±0.45 8.69±0.48###.\$\$\$ 8.43±0.38###.\$\$\$ VHF 9.23±0.43\$ 6.12±0.30###.\$\$\$.\$\$\$.\$\$\$.\$\$\$.\$\$\$.\$\$\$\$ 5.73±0.35###.\$\$\$.\$\$\$\$.\$		VHF	2.49 ± 0.28	2.04±0.22###	2.06±0.22###
HF 10.04±0.45 8.69±0.48##,\$\$\$ 8.43±0.38##,\$\$\$ VHF 9.23±0.43\$ 6.12±0.30##,\$\$\$.\$\$\$.£££ 5.73±0.35##,\$\$\$.\$\$\$.£££ IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·1-1) LF 0.90±0.09 0.82±0.08 0.82±0.08# HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#,\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3#,\$ 135±3 VHF 130±3 136±3#,\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	IgG	P	10.58 ± 0.45	11.02 ± 0.50	10.59 ± 0.48
IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·1¹) LF 0.90±0.09 0.82±0.08 0.82±0.08### HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#.\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3#,\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	$(g \cdot l^{-1})$	LF	9.25 ± 0.55 §	8.53 ± 0.54 §§§	8.70 ± 0.55 §§
IgM P 0.83±0.10 0.86±0.10 0.89±0.11 (g·1·) LF 0.90±0.09 0.82±0.08 0.82±0.08# HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4*,\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3*,\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		HF	10.04 ± 0.45	$8.69 \pm 0.48^{\text{###,§§§}}$	$8.43{\pm}0.38^{\#\#,\S\S}$
(g·1·1) LF 0.90±0.09 0.82±0.08 0.82±0.08# HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#.\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3#.\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		VHF	9.23±0.43§	$6.12\pm0.30^{\text{###,§§§,$$$,£££}}$	5.73 ± 0.35
HF 0.86±0.08 0.79±0.07## 0.73±0.08### VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#,\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3#,\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	IgM	P	0.83 ± 0.10	0.86 ± 0.10	0.89 ± 0.11
VHF 0.91±0.10 0.62±0.06### 0.66±0.06### SBP P 129±3 135±4#,\$ 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3#,\$ 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	$(g \cdot l^{-1})$	LF	0.90 ± 0.09	0.82 ± 0.08	$0.82{\pm}0.08^{\#}$
SBP P 129±3 135±4 ^{#,\$} 131±3 (mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3 ^{#,\$} 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		HF	0.86 ± 0.08	$0.79\pm0.07^{\#}$	$0.73 \pm 0.08^{\#\#}$
(mmHg) LF 129±2 126±2 132±3 HF 132±3 133±4 135±3 VHF 130±3 136±3 ^{#,S} 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		VHF	0.91 ± 0.10	$0.62 \pm 0.06^{\#\#}$	$0.66 \pm 0.06^{\#\#}$
HF 132±3 133±4 135±3 VHF 130±3 136±3 ^{#,\$} 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	SBP	P	129±3	135±4 ^{#,\$}	131±3
VHF 130±3 136±3 ^{#,\$} 135±3 DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2	(mmHg)	LF	129±2	126±2	132±3
DBP P 81±2 81±3 81±2 (mmHg) LF 79±2 79±2 78±2 HF 82±2 79±2 81±2		HF	132±3	133±4	135±3
(mmHg) LF 79 ± 2 79 ± 2 78 ± 2 HF 82 ± 2 79 ± 2 81 ± 2		VHF	130±3	136±3 ^{#,\$}	135±3
HF 82±2 79±2 81±2	DBP	P	81±2	81±3	81±2
	(mmHg)	LF	79±2	79±2	78±2
VHF 82±2 77±5 81±2		HF	82±2	79±2	81±2
		VHF	82±2	77±5	81±2

Values are means \pm SEM. RBC, red blood cell; CRP, C-reactive protein; HbA1c, glycated haemoglobin; CK, creatine kinase; IgA, immunoglobulin A; IgG, immunoglobulin G, IgM, immunoglobulin M; SBP, systolic blood pressure; DBP, diastolic blood pressure. *p<0.05, **p<0.01, ***p<0.001 different from D0, same group. *p<0.05, **p<0.01, ***p<0.001 D84 vs D42, same group. *p<0.05, \$\$p<0.01, \$\$\$p<0.01, \$\$\$p<0.01 different from P, same time. \$p<0.05, \$\$p<0.01, \$\$\$p<0.01 different from LF, same time. \$p<0.01, \$\$\$p<0.01, \$\$\$\$p<0.01 different from HF, same time. n=15 in Placebo (P), n=16 in Low-frequency (LF), High-frequency and Very high-frequency (VHF).

Table 2. Effects of repeated plasma donation on body composition

		D0	D42	D84
Body mass	P	77.4±3.8	77.7±3.8	77.2±3.7
(kg)	LF	78.9 ± 2.6	79.1±2.7	79.5 ± 2.5
	HF	82.8±2.1	83.7±2.5	83.5±2.5
	VHF	80.7±2.9	80.2 ± 2.8	80.7 ± 3.0
BMI	P	23.6 ± 0.9	23.7 ± 0.9	23.6 ± 0.9
(kg·m ⁻²)	LF	23.7 ± 0.6	23.6 ± 0.6	23.8 ± 0.7
	HF	24.4 ± 0.7	24.7 ± 0.8	24.7 ± 0.8
	VHF	24.0 ± 0.6	23.8 ± 0.5	24.0 ± 0.6
BMC	P	2.87 ± 0.12	2.88 ± 0.12	2.91 ± 0.12
(kg)	LF	2.97 ± 0.13	2.95 ± 0.13	2.98 ± 0.13
	HF	2.95 ± 0.06	2.95 ± 0.05	$2.93\pm0.06^{**}$
	VHF	2.89 ± 0.11	2.87 ± 0.11	2.88 ± 0.11
Fat mass	P	12.7±1.9	12.4 ± 1.8	$13.3{\pm}1.9^*$
(kg)	LF	11.5±1.1	11.5±1.1	11.8 ± 1.1
	HF	14.6±1.4	15.1±1.5	15.4±1.5#
	VHF	14.1±1.3	13.7±1.3	14.9±1.4 ^{#,**}
FFM	P	60.6 ± 2.3	60.9 ± 2.2	59.8±2.1 ^{#,**}
(kg)	LF	63.2±1.7	63.2 ± 1.8	63.2 ± 1.7
	HF	63.9±1.2	64.2 ± 1.2	63.6±1.2
	VHF	61.8 ± 2.0	61.9±1.8	61.5±1.9
FFM + BMC	P	63.5±2.4	63.8 ± 2.3	$62.7 \pm 2.2^{\#,**}$
(kg)	LF	66.1±1.8	66.1 ± 1.9	66.2 ± 1.7
	HF	66.8±1.2	67.2 ± 1.2	66.6 ± 1.2
	VHF	64.7±2.1	64.8 ± 1.9	64.3 ± 1.9
% Fat	P	15.9 ± 1.6	15.5±1.6	16.8±1.6**
	LF	14.6 ± 1.0	14.5 ± 1.0	14.9 ± 1.0
	HF	17.5±1.3	17.9 ± 1.4	18.3 ± 1.4
	VHF	17.7±1.2	17.1 ± 1.2	18.4±1.2**

Values are means \pm SEM. BMI, body mass index; BMC, bone mineral content; FFM, fat free mass. $^{\#}p<0.05$ vs D0, same group. $^{**}p<0.01$ vs D42, same group. n=15 in Placebo (P), n=16 in Low-frequency (LF), High-frequency (HF) and Very high-frequency (VHF).

Table 3. Effects of repeated plasma donation on exercise performance

		D 0	D42	D84
Lactate 190W	P	3.5±0.5	3.5±0.5	3.3±0.4
$(\text{mmol} \cdot l^{-1})$	LF	2.9 ± 0.5	2.8 ± 0.6	3.1 ± 0.6
	HF	3.0 ± 0.2	3.2 ± 0.4	3.1 ± 0.3
	VHF	3.9 ± 0.8	3.8 ± 0.6	3.3 ± 0.4
Lactate post	P	11.2 ± 0.7	10.2 ± 0.7	10.1 ± 0.8
$(mmol \cdot l^{-1})$	LF	9.4 ± 0.7	9.3 ± 0.7	9.4 ± 0.5
	HF	10.1 ± 0.8	9.8 ± 0.6	9.6 ± 0.7
	VHF	11.6±0.5\$	11.1 ± 0.4	10.9 ± 0.5
HRmax	P	185±3	185±2	185±3
(bpm)	LF	180±5	181±5	180±5
	HF	184±4	185±3	184±3
	VHF	188 ± 2	189±2	189 ± 2
VEmax	P	150±8	150±9	145±8
(1·min ⁻¹)	LF	141 ± 7	145±7	144±9
	HF	145±3	148 ± 4	146±4
	VHF	142 ± 7	140±6	140±5
Max power	P	282 ± 13	279±14	278 ± 13
output	LF	$292{\pm}14$	283±17#	285±15
(watt)	HF	276 ± 9	$275{\pm}10$	273 ± 10
	VHF	$273{\pm}11$	260±10#	260±11#
VO2peak	P	49.0 ± 2.8	51.6 ± 2.7	50.0 ± 2.5
$(ml \cdot min^{-1} \cdot kg^{-1})$	LF	46.3 ± 2.3	49.2 ± 2.8	47.7 ± 2.3
	HF	44.3 ± 1.3	47.5±1.9##	$45.1 \pm 1.5^*$
	VHF	44.1±1.9	45.5 ± 2.1	45.0 ± 2.0
Oxygen pulse	P	0.20 ± 0.01	$0.21 \pm 0.01^{\#}$	0.21 ± 0.01
(ml·beat-1·kg-1)	LF	0.20 ± 0.01	0.21 ± 0.01	$0.21 \pm 0.01^{\#}$
	HF	0.20 ± 0.01	$0.21\pm0.03^{\#\#}$	0.20 ± 0.03
	VHF	0.19 ± 0.01	0.19 ± 0.01	0.19 ± 0.01
Quadriceps	P	84±4	79±4	78±4 [#]
1RM	LF	81±4	81±5	82±5
(kg)	HF	84±4	82±3	81±4
	VHF	83±3	84±4	86±4
Max arm	P	43±2	43±2	45±2
strength	LF	44±2	45±2	45±3
(kg)	HF	41±1	41±2	41±1
	VHF	44±2	43±2	43±2

Values are means \pm SEM. HR, heart rate; VE, ventilation; VO₂peak, peak oxygen consumption; RER, respiratory exchange ratio. p<0.05 vs LF, same time. p<0.05, p<0.05, p<0.05, same group. p<0.05 vs D42, same group. p<0.05 in Placebo (P), p<0.05 in Low-frequency (LF), High-frequency (HF) and Very high-frequency (VHF).

Table S1. *p-values from the global ANOVA analyses*

	Group	Time	G*T	LF vs P	HF vs P	VHF vs P	HF vs LF	VHF vs LF	VHF vs HF
RBC	0.7714	0.8316	0.0001	0.5340	0.6592	0.7527	0.8537	0.3422	0.4430
Haemoglobin	0.2233	0.9179	< 0.0001	0.4014	0.8031	0.1079	0.2702	0.4275	0.0606
Haematocrit	0.2768	0.4828	0.0006	0.4319	0.8595	0.1209	0.3298	0.4320	0.0809
Reticulocyte	0.0625	0.0032	0.0277	0.8766	0.0309	0.0771	0.0413	0.1006	0.6755
Iron	0.0023	0.7698	0.3998	0.3015	0.0573	0.0003	0.3674	0.0058	0.0560
Ferritin	0.0093	0.0003	0.0014	0.9074	0.0183	0.0101	0.0223	0.0124	0.8161
CRP	0.5313	0.2867	0.9484	0.2674	0.1925	0.6533	0.8415	0.4983	0.3807
Glycemia	0.2163	0.0322	0.0361	0.3968	0.8885	0.2266	0.4736	0.0396	0.1728
Insulinemia	0.7541	0.0155	0.4047	0.9930	0.5582	0.3752	0.5585	0.3732	0.7594
HbA1c	0.7651	0.0962	0.0007	0.5003	0.5150	0.8803	0.9813	0.4026	0.4157
CK	0.4041	0.4766	0.4489	0.7384	0.9659	0.1424	0.7684	0.2498	0.1497
Total cholesterol	0.3562	< 0.0001	0.3901	0.9402	0.7967	0.1395	0.7355	0.1153	0.2131
Albumin	0.0193	0.0002	< 0.0001	0.2828	0.5907	0.0035	0.5835	0.0520	0.0139
IgA	0.5834	< 0.0001	< 0.0001	0.1852	0.4879	0.7155	0.5162	0.3259	0.7370
IgG	< 0.0001	< 0.0001	< 0.0001	0.0044	0.0091	< 0.0001	0.7874	0.0029	0.0013
IgM	0.6411	< 0.0001	< 0.0001	0.9522	0.5045	0.2738	0.5368	0.2928	0.6616
SBP	0.5625	0.0615	0.1499	0.4532	0.2608	0.5819	0.2608	0.1888	0.8481
DBP	0.7827	0.4888	0.9039	0.3464	0.8636	0.5864	0.4344	0.6830	0.7060
Body mass	0.5687	0.4193	0.3678	0.6449	0.1703	0.4591	0.3509	0.7755	0.5158
BMI	0.8068	0.2363	0.3311	0.8858	0.3662	0.7542	0.4391	0.8632	0.5469
BMC	0.8843	0.3905	0.0803	0.5429	0.6718	0.9546	0.8505	0.4990	0.6253
Fat mass	0.3698	0.0002	0.7008	0.0819	0.6340	0.3163	0.7617	0.9787	0.9954
FFM + BMC	0.5218	0.0119	0.7919	0.2558	0.1870	0.6342	0.8495	0.4990	0.8495
FFM	0.5051	0.0124	0.7596	0.2492	0.1751	0.6160	0.8328	0.5050	0.3810
%Fat	0.2492	0.0002	0.7500	0.4295	0.3613	0.3625	0.0864	0.0868	0.9980
Quadriceps 1RM	0.8626	0.3709	0.4308	0.9542	0.7622	0.4464	0.8035	0.4748	0.6405
Arm max strength	0.5259	0.4520	0.5672	0.6111	0.3487	0.9299	0.1445	0.5446	0.3875
Lactate 190W	0.6069	0.8933	0.9188	0.5094	0.6642	0.5529	0.8125	0.2127	0.3016
Lactate post	0.1126	0.0618	0.8807	0.1553	0.3513	0.4126	0.6130	0.0250	0.0781
Max power output	0.6435	0.0055	0.5343	0.7727	0.7668	0.3566	0.5524	0.2203	0.5237
VO ₂ peak	0.2584	0.0014	0.7932	0.3942	0.1223	0.0668	0.4745	0.3100	0.7621
VEmax	0.8337	0.7687	0.8645	0.5660	0.8345	0.3992	0.7103	0.7839	0.5186
HRmax	0.3332	0.7756	0.9383	0.2922	0.9427	0.4481	0.3182	0.0684	0.3991
Oxygen pulse	0.2920	0.0015	0.5445	0.9715	0.8069	0.1093	0.7761	0.0969	0.1661

RBC, red blood cell; CRP, C-reactive protein; HbA1c, glycated haemoglobin; CK, creatine kinase; IgA, immunoglobulin A; IgG, immunoglobulin G, IgM, immunoglobulin M; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; BMC, bone mineral content; FFM, fat free mass; 1RM, 1-repetition maximum; VO₂peak, peak oxygen consumption; VE, ventilation; HR, heart rate; RER, respiratory exchange ratio; P, placebo; LF, low-frequency; HF, high-frequency; US, US scheme. n=15 in Placebo, n=16 in Low-frequency (LF), High-frequency (HF) and Very high-frequency (US).

Table S2. Subjects characteristics at the start of the study

	Placebo		Donation		
		Low- frequency	High- frequency	Very high- frequency	p-value
Age (y)	35.9±2.0	37.7±2.2	31.4±1.8	31.6±2.1	0.071
Body mass (kg)	77.4 ± 3.8	78.9 ± 2.6	82.8 ± 2.1	80.7 ± 2.9	0.595
Height (cm)	180.7 ± 2.0	182.6 ± 2.0	184.4 ± 1.9	183.0 ± 2.0	0.720
BMI $(kg \cdot m^{2-1})$	23.6 ± 0.9	23.7 ± 0.6	24.4 ± 0.7	24.0 ± 0.6	0.840
Sport/week (h)	5.4 ± 0.8	5.9 ± 0.9	5.0 ± 0.7	4.9 ± 0.9	0.620
VO2peak (ml·kg-1·min-1)	49.0 ± 2.8	46.3 ± 2.3	44.3 ± 1.3	44.1 ± 1.9	0.364
Donation history	0[2]	0[1]	1[2]	2[4]	0.281

Values are means \pm SEM, except for donation history where the number of plasma donations until 3 months prior to the study was expressed as a median [IQR, interquartile range]. A mixed model was used for all variables to test differences between groups except for donation history, for which a Kruskal-Wallis test was used. BMI, body mass index; VO₂peak, peak oxygen consumption. n=15 in Placebo, n=16 in Low-frequency, High-frequency and Very high-frequency.

Table S3. Number of clinical adverse events in each group

	Placebo	I	Oonation	
Adverse events of donation		LF	HF	VHF
A. Local Symptoms:	0	0	3	2
1.Blood outside vessel:	0	0	3	2
HaematomaArterial puncture	0 0	0 0	3	2 0
2. Arm pain				
Nerve injury/irritation	0	0	0	0
3.Localized infection/inflammation of vein or soft tissues	0	0	0	0
4. Other major blood vessel injury	0	0	0	0
 Deep Venous Thrombosis (DVT) Arteriovenous fistula Compartment syndrome Brachial artery pseudoaneurysm 	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0
B. Generalized symptoms – Vasovagal Reactions	0	0	1	4
 Vasovagal Reaction, no loss of consciousness (LOC) Vasovagal Reaction, loss of consciousness 	0 0	0 0	1 0	4 0
C. Related to apheresis	0	0	0	0
Citrate reactionsHaemolysisAir embolism	0 0 0	0 0 0	0 0 0	0 0 0
D. Allergic reactions	0	0	0	0
Local allergic reactionGeneralized (anaphylactic) reaction	0	0	0 0	0 0
E. Other serious adverse events	0	0	0	0
 Acute cardiac symptoms (other than myocardial infarction or cardiac arrest). Myocardial infarction 	0	0	0	0
 Cardiac arrest Transient Ischemic Attack (TIA) Cerebrovascular accident Death 	0 0 0	0 0 0	0 0 0	0 0 0
F. Other	0	0	0	6
• Anaemia	0	0	0	6
Total	0	0	4	12

n=15 (45 donations) in the placebo group, n=16 (47 donations) in the low-frequency (LF) group, n=16 (139 donations) the high-frequency (HF) group and n=16 (352 donations) in the very-high frequency (VHF) group.